Summit Therapeutics Inc (SMMT)

Summit Therapeutics' stock price has experienced significant volatility over the past six months. Analyst ratings and price targets have varied, with some analysts upgrading the stock and setting high price targets, while others have downgraded it. The FDA's acceptance of the BLA for ivonescimab was viewed positively. The company also announced a clinical trial collaboration with GSK and reported inducement grants. At the end of Q3 2025, Summit Therapeutics held $238.6 million in cash and equivalents, which increased to $710 million following a private placement.

The demand for Summit Therapeutics' products and services is primarily driven by medical need and disease prevalence rather than seasonal fluctuations. Therefore, there is no indication of significant demand seasonality for Summit Therapeutics' products.

Summit Therapeutics, Inc. is a biopharmaceutical oncology company focused on discovering, developing, and commercializing medicinal therapies. Their primary focus is on precision oncology treatments and novel antibiotics for serious infectious diseases, with their lead candidate being ivonescimab, a bispecific antibody in Phase III clinical trials for non-small cell lung cancer and other solid tumors. Previously, they focused on Clostridioides difficile infection (CDI) with ridinilazole.

Summit Therapeutics is headquartered in Miami, Florida, and maintains operations in North America to support clinical development and regulatory activities across the United States and Europe. The company's license territories for ivonescimab include the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa. Ivonescimab was developed by Akeso, Inc., which holds the license for the rest of the world, primarily China.

Summit Therapeutics' brand reputation is largely influenced by its clinical pipeline and regulatory progress. The FDA's acceptance of the BLA for ivonescimab is a significant positive event. Analyst coverage is strong, with a consensus rating of "Moderate Buy". The company's mission to resolve serious unmet medical needs and its focus on transformative medicines also contribute positively to its reputation.

Summit Therapeutics Inc. has 385 institutional owners and shareholders holding a total of 107,280,957 shares. Robert Duggan holds 77.95% of equities, followed by Michelle Xia (4.306%) and Mahkam Zanganeh (3.466%). Individuals account for approximately 86.16% of the ownership, while institutional ownership stands at about 11.7%.